Anti Rh D Immunoglobulin Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 250 IU, 500IU, 1500IU
Reference Brands: RhoGAM (USA), HyperRho (EU/LATAM), Immunate-R (India)
Category:
Plasma Products
Injection contains particular proteins isolated from human blood plasma. These proteins are a type of antibody. The active ingredient of this medicine is an antibody called anti-D (Rh) immunoglobulin which works against the Rhesus factor. Rhesus factors are a characteristic of red blood cells. People with Rhesus factor D in their blood are known as Rh positive, and those who do not have Rhesus factor D are known as Rh-negative.
ANTI RH D IMMUNOGLOBULIN is available in Injection
and strengths such as 250 IU, 500IU, 1500IU.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, ANTI RH D IMMUNOGLOBULIN is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
ANTI RH D IMMUNOGLOBULIN can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
When an Rh-negative mother is carrying an Rh-positive baby, the mother's antibodies cross the placenta and attacks the blood cells of the baby, resulting in haemolytic disease.
Rho(D) Immune Globulin (RhIG) is a plasma-derived immunoglobulin used primarily for the prevention of Rh isoimmunization in Rh-negative pregnant women and for the treatment of immune thrombocytopenic purpura (ITP). In Rh-negative pregnancies, RhIG provides passive immunity by neutralizing fetal Rh-positive red blood cells that may enter the maternal circulation, thereby preventing the maternal immune system from producing antibodies that could cause hemolytic disease of the newborn in current or future pregnancies. In ITP, RhIG helps increase platelet counts by modulating the immune response against platelets.
RhIG is prepared from human plasma containing high levels of anti-D antibodies, purified to ensure safety and efficacy. It is typically administered intramuscularly or intravenously, with the dose calculated based on maternal body weight or the clinical indication. Common adverse effects are mild and may include local pain, erythema, or low-grade fever. RhIG is contraindicated in individuals with a history of severe allergic reactions to immunoglobulin products or IgA deficiency with antibodies against IgA. Its rapid action, safety profile, and critical role in preventing hemolytic disease of the newborn make RhIG an essential therapy in maternal-fetal medicine and select hematologic conditions.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing